Sialylated and Fucosylated HMOs for Infant Bone Mineral Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infant formulae lack essential nutrients found in breast milk, leading to lower bone mineral density and architecture in formula-fed infants compared to breastfed ones, necessitating a composition that promotes bone health and strength.
Innovation Solution
A composition comprising a mixture of sialylated and fucosylated human milk oligosaccharides (HMOs) is used to enhance bone development and strength by increasing bone mineral density and reducing cortical and trabecular porosity, which can be incorporated into infant formulas and nutritional products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If infant formulae are used as substitutes for breast milk, then feeding convenience and nutritional control are improved, but bone mineral density and bone architecture deteriorate
Solution Approach 1:
The patent modifies the chemical composition parameters of infant formula by adding specific HMOs (sialylated and fucosylated oligosaccharides) to change the biological effects on bone metabolism. This allows the formula to maintain feeding convenience while improving bone mineral density through targeted compositional changes.
Solution Approach 2:
The patent creates a composite nutritional composition by combining multiple components including proteins, fats, carbohydrates, vitamins, minerals, and specifically sialylated and fucosylated HMOs. This composite approach allows the formula to provide comprehensive nutrition while specifically addressing bone health through the synergistic effects of multiple nutrients.
2Ease of manufacture
If standard infant formula composition is used, then manufacturing simplicity is maintained, but bone strength and cortical architecture deteriorate
Solution Approach 1:
The patent introduces specific HMO components with defined chemical structures and concentrations to modify the nutritional profile. These parameter changes are implemented through standard industrial mixing and formulation processes, maintaining manufacturing simplicity while achieving improved bone strength through targeted nutritional enhancement.
3Strength
If breast milk is used as the primary nutrition source, then bone mineral density and architecture are improved, but nutritional control and consistency deteriorate
Solution Approach 1:
The patent establishes precise compositional parameters for HMO content, protein ratios, fat composition, and micronutrient levels in infant formula. This allows manufacturers to produce nutritionally consistent products that replicate the beneficial bone-health properties of breast milk while maintaining standardized quality and composition across batches.
Solution Approach 2:
The patent creates a standardized composite nutritional formulation that combines multiple components in specific ratios and concentrations. This composite approach enables consistent reproduction of breast milk's beneficial effects on bone health while maintaining nutritional control and composition stability through standardized manufacturing processes.
Data Source
AI summary
The invention relates to the use of composition comprising sialylated and fucosylated human milk oligosaccharides (HMOs) for enhancing bone development and/or bone strength, preferably a nutritional composition for infants or young children.